title: Regulatory effect of nerve growth factor in alpha9beta1 integrin-dependent progression of glioblastoma.
abstract: In the present study we described the role of alpha9beta1 integrin in glioblastoma progression following its interaction with nerve growth factor (NGF). The level of expression of alpha9beta1 on astrocytomas is correlated with increased grade of this brain tumor and is highest on glioblastoma, whereas normal astrocytes do not express this integrin. Two glioblastoma cell lines, LN229 and LN18, that are alpha9beta1 integrin positive and negative, respectively, were used for alpha9beta1 integrin-dependent NGF-induced tumor progression. NGF was a significant promoter of promigratory and pro-proliferative activities of glioblastoma cells through direct interaction with alpha9beta1 integrin and activation of MAPK Erk1/2 pathway. The level of NGF increases approximately threefold in the most malignant glioma tissue when compared with normal brain. This increase is related to secretion of NGF by tumor cells. Specific inhibitors of alpha9beta1 integrin or gene silencing inhibited NGF-induced proliferation of LN229 cell line to the level shown by LN18 cells. VLO5 promoted alpha9beta1-dependent programmed cell death by induction of intrinsic apoptosis pathway in cancer cells. LN229 cells were rescued from proapoptotic effect of VLO5 by the presence of NGF. This disintegrin significantly inhibited tumor growth induced by implantation of LN229 cells to the chorioallantoic membrane (CAM) of quail embryonic model, and this inhibitory effect was significantly abolished by the presence of NGF. alpha9beta1 integrin appears to be an interesting target for blocking the progression of malignant gliomas, especially in light of the stimulatory effect of NGF on the development of these tumors and its ability to transfer proapoptotic signals in cancer cells.
authors.affiliation: Department of Neuroscience, Center for Neurovirology and Cancer Biology, School of Medicine, Temple University, Philadelphia, PA, USA.
authors.forename: Meghan C
authors.initials: MC
authors.lastname: Brown
authors.forename: Izabela
authors.initials: I
authors.lastname: Staniszewska
authors.forename: Philip
authors.initials: P
authors.lastname: Lazarovici
authors.forename: George P
authors.initials: GP
authors.lastname: Tuszynski
authors.forename: Luis
authors.initials: L
authors.lastname: Del Valle
authors.forename: Cezary
authors.initials: C
authors.lastname: Marcinkiewicz
mesh_terms: D000818:Animals; D017209:Apoptosis; D015153:Blotting, Western; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D018450:Disease Progression; D004797:Enzyme-Linked Immunosorbent Assay; D005909:Glioblastoma / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D016023:Integrins / Q000378:metabolism*; D020932:Nerve Growth Factor / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays
chemical_list: D016023:Integrins; C113256:integrin alpha 9 beta 1; D020932:Nerve Growth Factor